Head to Head Comparison: Mirum Pharmaceuticals (NASDAQ:MIRM) versus Immatics (NASDAQ:IMTX)

Mirum Pharmaceuticals (NASDAQ:MIRM) and Immatics (NASDAQ:IMTX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Earnings and Valuation

This table compares Mirum Pharmaceuticals and Immatics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31 million	10.45	-$23.36 million	($14.55)	-5.77
Immatics	$54.60 million	21.13	-$222.26 million	($1.86)	-4.54

Mirum Pharmaceuticals has higher revenue and earnings than Immatics. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Mirum Pharmaceuticals has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Immatics has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.

Insider and Institutional Ownership

64.4% of Immatics shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 3.3% of Immatics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Mirum Pharmaceuticals and Immatics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Immatics	-495.71%	-47.41%	-39.45%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Mirum Pharmaceuticals and Immatics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1	0	13	1	2.93
Immatics	1	1	6	0	2.62

Mirum Pharmaceuticals currently has a consensus target price of $142.56, suggesting a potential upside of 69.88%. Immatics has a consensus target price of $20.60, suggesting a potential upside of 144.08%. Given Immatics’ higher possible upside, analysts plainly believe Immatics is more favorable than Mirum Pharmaceuticals.

Summary

Mirum Pharmaceuticals beats Immatics on 9 of the 15 factors compared between the two stocks.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.